ADA Scientific Sessions 2025 Abstract

Targeting Activin Type II Receptors—Develop Monoclonal Antibodies LAE102, LAE103, and LAE123 as Candidate Therapeutics for Muscle Growth and Fat Reduction

By Ruipeng Zhang, Mengxue Yang, Jianxin Gu, Chris Lu

Experiments in animalsInterventions

The paper

Ruipeng Zhang, Mengxue Yang, Jianxin Gu, Chris Lu

Shanghai

ADA Scientific Sessions 2025 Abstract, 13 Jun 2025

Presented at ADA Scientific Sessions 2025, poster 861-P

doi.org/10.2337/db25-861-p

JCI Insight6 Oct 2026
Antibody reduced fat while preserving lean mass in mice
Cell Metabolism8 Oct 2026
A triple-target drug cut body weight by up to 19.7% in a trial